# Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

> **NCT06458803** · — · COMPLETED · sponsor: **Tongji Hospital** · enrollment: 52 (actual)

## Conditions studied

- Refractory Thrombocytopenia
- Connective Tissue Diseases

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT06458803
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-06
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-11-19
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06458803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06458803, "Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06458803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*